Development and evaluation of 2,4‐disubstituted‐5‐aryl pyrimidine derivatives as antibacterial agents

Abstract

AbstractDesigning novel candidates as potential antibacterial scaffolds has become crucial due to the lack of new antibiotics entering the market and the persistent rise in multidrug resistance. Here, we describe a new class of potent antibacterial agents based on a 5‐aryl‐N2,N4‐dibutylpyrimidine‐2,4‐diamine scaffold. Structural optimization focused on the 5‐aryl moiety and the bioisosteric replacement of the side chain linker atom. Screening of the synthesized compounds focused on a panel of bacterial strains, including gram‐positive Staphylococcus aureus strains (Newman MSSA, methicillin‐ and vancomycin‐resistant), and the gram‐negative Escherichia coli (ΔAcrB strain). Several compounds showed broad‐spectrum antibacterial activity with compound 12, bearing a 4‐chlorophenyl substituent, being the most potent among this series of compounds. This frontrunner compound revealed a minimum inhibitory concentration (MIC) value of 1 µg/mL against the S. aureus strain (Mu50 methicillin‐resistant S. aureus/vancomycin‐intermediate S. aureus) and an MIC of 2 µg/mL against other tested strains. The most potent derivatives were further tested against a wider panel of bacteria and evaluated for their cytotoxicity, revealing further potent activities toward Streptococcus pneumoniae, Enterococcus faecium, and Enterococcus faecalis. To explore the mode of action, compound 12 was tested in a macromolecule inhibition assay. The obtained data were supported by the safety profile of compound 12, which possessed an IC50 of 12.3 µg/mL against HepG2 cells. The current results hold good potential for a new class of extended‐spectrum antibacterial agents.